초록 ▼

Embodiments concern methods and compositions involving miR-34 mimics, including miR-34a and miR-34c mimics. In some embodiments, there are double-stranded RNA molecules with modified nucleotides having an active strand with a miR-34a sequence and a complementary passenger strand. In additional embod

Embodiments concern methods and compositions involving miR-34 mimics, including miR-34a and miR-34c mimics. In some embodiments, there are double-stranded RNA molecules with modified nucleotides having an active strand with a miR-34a sequence and a complementary passenger strand. In additional embodiments, there are double-stranded RNA molecules with modified nucleotides having an active strand with a miR-34c sequence and a complementary passenger strand.

대표청구항 ▼

1. A double-stranded, blunt-ended RNA molecule 23 or 24 basepairs in length comprising: a) an active strand comprising a sequence that is at least 90% identical to SEQ ID NO:5 from 5′ to 3′; andb) a passenger strand comprising a sequence that is at least 60% complementary to the active strand, a ter

1. A double-stranded, blunt-ended RNA molecule 23 or 24 basepairs in length comprising: a) an active strand comprising a sequence that is at least 90% identical to SEQ ID NO:5 from 5′ to 3′; andb) a passenger strand comprising a sequence that is at least 60% complementary to the active strand, a terminal modification of the nucleotide at the 5′ end, and modified nucleotides in the first and last two nucleotides of the passenger strand. 2. The RNA molecule of claim 1, wherein the passenger strand comprises modified nucleotides located at a subset of positions, wherein the subset is 1 (G), 2 (C), and 3 (A) and/or 22 (C), and 23 (U) relative to SEQ ID NO:6. 3. The RNA molecule of claim 1, wherein the passenger strand comprises a modified nucleotide located at positions 1 (G), 2 (C), and 3 (A) relative to SEQ ID NO:6. 4. The RNA molecule of claim 1, wherein the passenger strand comprises a modified nucleotide located at positions 1 (G), 2 (C), 3 (A), 22 (C), and 23 (U) relative to SEQ ID NO:6. 5. The RNA molecule of claim 1, wherein the passenger strand further comprises a modified nucleotide located at positions 4 (A), 7 (A), 8 (G), 9 (C), 10 (U), 11 (A), 12 (A), 13 (C), 14 (U), 19 (U), and/or 21 (C) relative to SEQ ID NO:6. 6. The RNA molecule of claim 1, wherein the passenger strand does not have a modified nucleotide located at positions 5 (U), 6 (C), 15 (A), and/or 16 (C) relative to SEQ ID NO:6. 7. The RNA molecule of claim 1, wherein the number of modified nucleotides in the passenger strand is four to eight. 8. The RNA molecule of claim 1, wherein the active strand comprises at least two modified nucleotides, wherein the modified nucleotides are not in the first two positions at the 5′ end. 9. The RNA molecule of claim 1, wherein the active strand does not have a modified nucleotide in the first two positions at the 5′ end. 10. The RNA molecule of claim 1, wherein the active strand does not comprise a modified nucleotide in the first or last two positions from the ends. 11. The RNA molecule of claim 1, wherein the active strand comprises modified nucleotides at positions 3 (G), 4 (C), 11 (G), 12 (U), 13 (A), 14 (G), 15 (C), 16 (C), 17 (U), and/or 18 (G) relative to SEQ ID NO:5. 12. A double-stranded, blunt-ended RNA molecule 23 or 24 basepairs in length comprising: a) an active strand comprising a sequence that is at least 90% identical to SEQ ID NO:5 from 5′ to 3′; andb) a passenger strand comprising a sequence that is at least 60% complementary to the active strand, and a terminal modification of the nucleotide at the 5′ end,the RNA molecule further comprising:(i) modified nucleotides at passenger strand positions 1 (G), 2 (C), 3 (A), 21 (C), 22 (C), and 23 (U) relative to SEQ ID NO:6;(ii) modified nucleotides at passenger strand positions 17 (A) and 18 (C) relative to SEQ ID NO:6;(iii) modified nucleotides at active strand positions 11 (G), 12 (U), 17 (U), and 18 (G) relative to SEQ ID NO:5; or(iv) modified nucleotides at active strand positions 3 (G), 4 (C), 17 (U), and 18 (G) relative to SEQ ID NO:5. 13. The RNA molecule of claim 12, comprising (i) and (ii). 14. The RNA molecule of claim 12, comprising (i) and further comprising modified nucleotides at passenger strand positions 11 (A), 12 (A), 13 (C), and 14 (U) relative to SEQ ID NO:6. 15. The RNA molecule of claim 13, further comprising modified nucleotides at passenger strand positions 11 (A), 12 (A), 13 (C), and 14 (U) relative to SEQ ID NO:6. 16. The RNA molecule of claim 15, further comprising (iii). 17. The RNA molecule of claim 12, comprising (iii), (iv), and further comprising modified nucleotides at active strand positions 13 (U), 14 (A), 15 (G), and 16 (C) relative to SEQ ID NO:5. 18. The RNA molecule of claim 17, further comprising (i). 19. The RNA molecule of claim 18, further comprising (ii). 20. The RNA molecule of claim 19, further comprising modified nucleotides at passenger strand positions 11 (A), 12 (A), 13 (C), and 14 (U) relative to SEQ ID NO:6. 21. The RNA molecule of claim 17, further comprising (ii). 22. The RNA molecule of claim 12, comprising (iii). 23. The RNA molecule of claim 12, comprising (i) and (iii). 24. The RNA molecule of claim 12, comprising (ii) and (iii). 25. The RNA molecule of claim 12, comprising (i), (ii), and (iii). 26. The RNA molecule of claim 1, wherein the modified nucleotides comprise sugar modifications. 27. The RNA molecule of claim 26, wherein the sugar modification comprises a 2′-OMe modification. 28. The RNA molecule of claim 1, wherein the terminal modification of the nucleotide at the 5′ end of the passenger strand is a C4-C12 amine linker. 29. The RNA molecule of claim 28, wherein the terminal modification of the nucleotide at the 5′ end of the passenger strand is a C6 amine linker. 30. The RNA molecule of claim 1, wherein the active strand is 100% identical to SEQ ID NO:5 from 5′ to 3′; and the passenger strand is 100% complementary to the active strand. 31. A pharmaceutical composition comprising the RNA molecule of claim 1. 32. A method for providing miR-34c activity to a cell comprising administering to the cell the RNA molecule of claim 1. 33. A method for decreasing cell proliferation comprising administering to the cell an effective amount of the RNA molecule of claim 1. 34. A method for inducing apoptosis in a cell comprising administering to the cell an effective amount of the RNA molecule of claim 1. 35. A method for treating cancer in a patient comprising administering to the patient a pharmaceutical composition comprising the RNA molecule of claim 1.